UNSPSC 51352013: Gestonorone caproate

This classification denotes a therapeutic progestin with the molecular formula C20H28O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H4G605B7VP, chemically known as 19-norpregn-4-ene-3,20-dione, 17-hydroxy- but more generally known as gestonorone, which bears US NIH Compound Identifier 102210. European Medicines Agency schedules Gestonorone caproate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07902MIG.

UNSPSC 51352013 Gestonorone caproate is a Commodity code for a specific synthetic progestin pharmaceutical used in hormone replacement and contraceptive therapies. State and local governments procure this drug through cooperative purchasing agreements that bundle it with broader generic pharmaceutical and over-the-counter product catalogs, rather than as a standalone line item. Solicitations under this code typically target pharmaceutical manufacturers and authorized distributors who can supply products meeting FDA requirements, current Good Manufacturing Practices (cGMP) certification, and Drug Supply Chain Security Act (DSCSA) compliance. The buying bodies include state health departments, Medicaid programs, state prison systems, county health clinics, and municipal hospitals that participate in multistate cooperative purchasing alliances. Vendors must maintain relationships with authorized wholesalers, manage NDC coding and inventory tracking systems, and accept administrative fee structures that reduce net reimbursement. Price competitiveness drives award decisions, often accounting for 75 percent of evaluation weight, with secondary consideration given to EDI capability, compliance with data format requirements, and pricing flexibility (flat rate, net price formats, or WAC-minus structures).

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products spanning participating states including Oregon. The solicitation requires manufacturers to supply through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with awarded contracts effective July 1, 2026 for an initial two-year term. Vendors must certify cGMP and DSCSA compliance, maintain $5,000,000 commercial general liability coverage and $2,000,000 network security and professional liability coverage, and accept a 3 percent administrative fee on purchases. Performance violations carry penalties ranging from $200 to $1,500. The RFP specifies no formal set-aside designations but emphasizes price competitiveness (75 percent weight) and contract compliance metrics. Award structure permits sole, dual, or multi-awards based on therapeutic need and patient safety considerations rather than preset dollar allocations.